|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Supplementary Table S3. Patient backgrounds in patients with drugs potentially associated with severe hypoglycemia classified as Categories I and II | | | | | | |
|  | whole | above | within the range | inappropriately below | *P* value |
| n (%) | 199 | 82 (41.2) | 77 (38.7) | 40 (20.1) |  |
| Age (years) | 74 (70, 79) | 71 (69, 80) | 74 (69, 78) | 76 (72, 78) | 0.0662 |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Number of female, n (%) | 88 (44.2) | | 40 (48.8) | | 34 (44.2) | | 14 (35.0) | | 0.3552 | |
| BMI (kg/m2) | 24.4 (22.0, 26.9) | | 25.5 (22.4, 28.7) | | 23.6 (21.2, 25.7) | | 23.5 (21.3, 26.5) | | 0.0278\* | |
| Diabetes duration (years) | 20 (12, 29) | | 21 (13, 28) | | 20 (10, 29) | | 20 (14, 30) | | 0.7873 | |
| HbA1c (%) | 7.5 (6.9, 8.1) | | 8.2 (7.9, 8.9) | | 7.2 (7.0, 7.6) | | 6.4 (6.1, 6.7) | | <0.001\* | |
| HbA1c (mmol/mol) | 58 (51, 65) | | 66 (62, 73) | | 55 (52, 59) | | 46 (43, 49) | | <0.001\* | |
| FPG (mg/dL) | 146 (122, 178) | | 160 (129, 200) | | 138 (120, 157) | | 135 (111, 162) | | 0.0021\* | |
| Fasting CPR (ng/mL) | 1.4 (0.7, 2.2) | | 1.5 (0.6, 2.3) | | 1.2 (0.6, 2.1) | | 1.4 (0.9, 2.0) | | 0.5296 | |
| eGFR | 58.1 (45.4, 70.3) | | 55.1 (44.1, 68.2) | | 62.1 (49.2, 71.9) | | 57.1 (46.1, 68.2) | | 0.1222 | |
| DASC-8 score, n (%) | 9 (8, 11) | | 10 (8, 12) | | 9 (8, 11) | | 10 (8, 11) | | 0.2269 | |
| Category I | 135 (67.8) | | 53 (64.6) | | 56 (72.7) | | 26 (65.0) | |  | |
| Category II | 64 (32.2) | | 29 (35.4) | | 21 (27.3) | | 14 (35.0) | | 0.5023 | |
| Category III | 0 (0) | | 0 (0) | | 0 (0) | | 0 (0) | |  | |
| Physically active (≥10METs/week), n (%) | 162 (81.4) | | 63 (76.8) | | 67 (87.0) | | 32 (80.0) | | 0.2483 | |
| Complications, n (%) |  | |  | |  | |  | | | |  | |
| Diabetic neuropathy | 146 (73.4) | | 64 (78.1) | | 57 (74.0) | | 25 (62.5) | | 0.1341 | | |
| Diabetic retinopathy | 84 (42.9) | | 37 (45.7) | | 32 (42.7) | | 15 (37.5) | | 0.6931 | | |
| Diabetic nephropathy | 115 (57.8) | | 48 (58.5) | | 40 (52.0) | | 27 (67.5) | | 0.2669 | | |
| Hypertension | 152 (76.4) | | 67 (81.7) | | 55 (71.4) | | 30 (75.0) | | 0.3044 | | |
| Dyslipidemia | 147 (73.9) | | 65 (79.3) | | 57 (74.0) | | 25 (62.5) | | 0.1410 | | |
| Stroke or TIA | 26 (13.1) | | 14 (17.1) | | 7 (9.1) | | 5 (12.5) | | 0.3260 | | |
| Cardiovascular disease | 42 (21.1) | | 19 (23.2) | | 15 (19.5) | | 8 (20.0) | | 0.8346 | | |
| Osteoporosis | 33 (16.6) | | 18 (22.0) | | 9 (11.7) | | 6 (15.0) | | 0.2107 | | |
| Malignancy | 53 (26.6) | | 18 (22.0) | | 20 (26.0) | | 15 (37.5) | | 0.1869 | |
| Social conditions, n (%) |  | |  | |  | |  | | 0.1161 | |
| Living with a partner | 108 (54.3) | | 38 (46.3) | | 48 (62.3) | | 22 (55.0) | |  | |
| Living with children | 41 (20.6) | | 24 (29.3) | | 9 (11.7) | | 8 (20.0) | |  | |
| Living with elder parents | 2 (1.0) | | 1 (1.2) | | 0 (0) | | 1 (2.5) | |  | |
| Living alone | 46 (23.1) | | 17 (20.7) | | 20 (26.0) | | 9 (22.5) | |  | |
| Nursing home stay | 2 (1.0) | | 2 (2.4) | | 0 (0) | | 0 (0) | |  | |
| Diabetes treatment, n (%) | |  | |  | |  | |  | |  | | |
| Drugs potentially associated with severe hypoglycemia | | 199 (100) | | 82 (100) | | 77 (100) | | 40 (100) | |  | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Insulin use | 134 (67.3) | 53 (64.6) | 55 (71.4) | 26 (65.0) | 0.6195 |
| Sulfonylurea | 52 (26.1) | 24 (29.3) | 20 (26.0) | 8 (20.0) | 0.5493 |
| Glinide | 47 (23.6) | 18 (22.0) | 19 (24.7) | 10 (25.0) | 0.8975 |
| α-glucosidase inhibitor | 29 (14.6) | 14 (17.1) | 11 (14.3) | 4 (10.0) | 0.5802 |
| Metformin | 93 (46.7) | 41 (50.0) | 33 (42.9) | 19 (47.5) | 0.6618 |
| Thiazolidine | 10 (5.0) | 3 (3.7) | 5 (6.5) | 2 (5.0) | 0.7158 |
| GLP‐1 receptor agonist | 44 (22.1) | 27 (32.9) | 13 (16.9) | 4 (10.0) | 0.0061\* |
| DPP-4 inhibitor | 117 (58.8) | 41 (50.0) | 47 (61.0) | 29 (72.5) | 0.0529 |
| SGLT2 inhibitor | 51 (25.6) | 26 (31.7) | 21 (27.3) | 4 (10.0) | 0.0330\* |
| Injecting oneself | 137 (93.2) | 56 (90.3) | 54 (94.7) | 27 (96.4) | 0.4765 |
| Number of concomitant antidiabetic drugs, n | 3 (2, 4) | 3 (2, 4) | 3 (2, 4) | 3 (2, 3) | 0.2366 |

Values are expressed as median (interquartile range) or number (%) of patients in each category. The Kruskal-Wallis test or chi-square test was used for comparisons of the parameters.

BMI: body mass index; FPG: fasting plasma glucose; CPR: C-peptide; eGFR: estimated glomerular filtration rate; GLP‐1: glucagon‐like peptide‐1; DPP‐4: dipeptidyl peptidase‐4; SGLT2: sodium-glucose cotransporter 2; TIA: transient ischemic attack